James Rolke
CIK 1693858 · Chief Executive Officer · last filed 2026-05-01
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.1K
Companies
2
Total Filings
50
Lifetime Open-Market Net
$31.7K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| REVBW | Chief Executive Officer | 214,738 | $0.01 | $2.1K | $0 | 6 | 2026-05-01 |
| LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | Chief Scientific Officer | 81,771 | $6.22 | $508.6K | $31.7K | 44 | 2020-06-02 |
Recent Filings · Page 3 of 5
50 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-10-02 | LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | Grant (A) | +107 | $800 | EDGAR |
| 2019-09-16 | LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | Grant (A) | +85 | $789 | EDGAR |
| 2019-09-03 | LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | Grant (A) | +98 | $797 | EDGAR |
| 2019-08-16 | LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | Grant (A) | +99 | $794 | EDGAR |
| 2019-08-02 | LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | Grant (A) | +112 | $796 | EDGAR |
| 2019-07-17 | LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | Grant (A) | +102 | $801 | EDGAR |
| 2019-07-01 | LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | Grant (A) | +101 | $794 | EDGAR |
| 2019-06-18 | LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | Grant (A) | +96 | $792 | EDGAR |
| 2019-06-03 | LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | Grant (A) | +174 | $797 | EDGAR |
| 2019-05-17 | LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | Grant (A) | +143 | $798 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.